Docetaxel

First-line treatment with carboplatin plus pemetrexed followed by maintenance pemetrexed appeared noninferior to docetaxel monotherapy in extending OS among older patients with advanced nonsquamous non-small cell lung cancer, according to results of a randomized phase 3 trial published in JAMA Oncology.

Pembrolizumab in combination with docetaxel substantially improved overall response rate and PFS compared with docetaxel alone among patients with non-small cell lung cancer whose disease progressed after platinum-based chemotherapy, according to results of a randomized phase 2 study published in JAMA Oncology.

Talazoparib monotherapy induced promising antitumor activity in men with metastatic castration-resistant prostate cancer who previously received docetaxel, according to the first interim analysis of the single-arm, phase 2 TALAPRO-1 study presented at Genitourinary Cancers Symposium.

High baseline BMI appeared to be independently associated with improved survival among patients with non-small cell lung cancer who received atezolizumab, according to results of a retrospective study published in JAMA Oncology.

BARCELONA, Spain — Cabazitaxel significantly improved outcomes compared with androgen receptor-targeted therapies for certain men with previously treated metastatic castration-resistant prostate cancer, according to results of the randomized CARD study presented at European Society for Medical Oncology Congress.

BARCELONA, Spain — The addition of upfront docetaxel chemotherapy to androgen deprivation therapy conferred durable, clinically significant benefit for men with low- and high-burden metastatic prostate cancer, according to results of the randomized phase 3 STAMPEDE trial presented at European Society for Medical Oncology Congress.

BARCELONA — Nivolumab led to a fivefold improvement in OS at 5 years compared with docetaxel among patients with previously treated advanced non-small cell lung cancer, according to pooled results from the CheckMate 017 and 057 trials presented at International Association for the Study of Lung Cancer World Conference on Lung Cancer.